Company news
Shanghai Xiao Fang Pharmaceutical Co., Ltd. Class A (SSE:603207) news
Shanghai Xiao Fang Pharmaceutical Co., Ltd. Class A news releases on 6ix. Latest, Sep 30, 2026: "SHANGHAI XIAO FANG PHARMACEUTICAL CO., LTD."Announcement…
Press releases & updates
"SHANGHAI XIAO FANG PHARMACEUTICAL CO., LTD."Announcement on Convening the 2026 Semi-annual Performance Briefing
September 29, 2026
"SHANGHAI XIAO FANG PHARMACEUTICAL CO., LTD."Announcement on Abnormal Fluctuations in Stock Trading
September 2, 2026
"SHANGHAI XIAO FANG PHARMACEUTICAL CO., LTD."Announcement on the Interim Profit Distribution Plan for 2026
August 26, 2026
"SHANGHAI XIAO FANG PHARMACEUTICAL CO., LTD."Announcement on Results of the Initial Grant under the 2026 Restricted Share Incentive Plan
August 25, 2026
"SHANGHAI XIAO FANG PHARMACEUTICAL CO., LTD."Announcement on Completion of the Election of Independent Directors
August 12, 2026
"SHANGHAI XIAO FANG PHARMACEUTICAL CO., LTD."Announcement on Completion of Industrial and Commercial Registration Change
August 7, 2026
"SHANGHAI XIAO FANG PHARMACEUTICAL CO., LTD."Announcement on Election of Independent Directors
July 22, 2026
"SHANGHAI XIAO FANG PHARMACEUTICAL CO., LTD."Announcement on Reply to Letter of Supervision and Inquiry on Information Disclosure of 2025 Annual Report
July 14, 2026
"SHANGHAI XIAO FANG PHARMACEUTICAL CO.,LTD."Announcement on the Resignation of the Independent Directors
July 1, 2026
Announcement on the 1st Granting of Restricted Stocks to Incentive Objects in 2026 Restricted Stock Incentive Plan
June 29, 2026
Announcement on Implementation of Dividend Distribution for 2025
June 25, 2026
Publicity Explanation and Verification Opinions of the Remuneration and Appraisal Committee of the Board of Directors on List of Initially Granted Incentive Objects in the 2026 Restricted Stock Incentive Plan
June 24, 2026
Announcement on Redemption of Partial Temporarily Idle Raised Funds Used for Cash Management
June 23, 2026
Announcement on Resolutions of the 11th Meeting of the 2nd Board of Directors
June 10, 2026
Announcement on Lifting Sales Restrictions and Listing for Circulation in the 1st Restriction Lifting Period for the 1st Grant under 2025 Restricted Stock Incentive Plan
June 8, 2026
Announcement on Convening Performance Briefing for 2025 and Q1 2026
June 2, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
May 21, 2026
Announcement on Completing Industrial and Commercial Change Registration
May 6, 2026
Report for Q1 2026
April 27, 2026
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
March 2, 2026
Notice on Convening the 1st Extraordinary General Meeting in 2026
February 12, 2026
Announcement on the Reserved Granting Results of the 2025 Restricted Stock Incentive Plan
February 3, 2026
Announcement on the Grant of Partial Reserved Restricted Stocks to Incentive Recipients under the 2025 Restricted Stock Incentive Plan
December 19, 2025
Announcement on Convening the Q3 2025 Performance Briefing
December 1, 2025
Announcement on Change of Sponsor Representative for Continuous Supervision
November 14, 2025
Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025
November 10, 2025
Announcement on Using Some Temporarily Idle Raised Funds for Cash Management
October 24, 2025
Announcement on Redemption at Maturity of Idle Raised Funds Used for Cash Management
October 10, 2025
Announcement on Entrusting Bojimed to Develop the Traditional Chinese Medicine Class 1.1 New Drug "Compound Platycodon Tincture" (for Treating Hair Loss)
September 25, 2025
Announcement on Convening the 2025 Semi-annual Performance Briefing
September 4, 2025
Announcement on Resolutions of the 5th Meeting of the 2nd Board of Directors
August 25, 2025
Announcement on Listing and Circulation of Partial Restricted Shares from Initial Public Offering
August 20, 2025
Announcement on Voluntary Disclosure of Cooperation with Shanghai Skin Disease Hospital to Develop Class 1.1 New Traditional Chinese Medicine Compound Platycladus Orientalis Tincture for the Treatment of Hair Loss
June 12, 2025
Announcement on Convening the 2024 Annual and Q1 2025 Performance Briefing
June 11, 2025
Announcement on Completion of Industrial and Commercial Change Registration
June 9, 2025
Announcement on Implementation of Dividend Distribution for 2024
June 3, 2025
Announcement on Resolution of the 2024 Annual General Meeting
May 22, 2025
Report for Q1 2025
April 29, 2025
Announcement on the Initial Granting Results of the 2025 Restricted Stock Incentive Plan
April 10, 2025
Announcement on Listing and Circulation of Restricted Shares in Offline Placement of Initial Public Offering
February 26, 2025
Announcement on the Initial Granting of Restricted Stock to the Incentive Objects of the 2025 Restricted Stock Incentive Plan
February 13, 2025
Board of Supervisors' Remarks on Verification Opinions on and Publicity of List of Incentive Objects under Restricted Stock Incentive Plan of 2025
February 7, 2025
Announcement on the Notice on Convening the 1st Extraordinary General Meeting in 2025
January 24, 2025
Announcement on the Replacement of Sponsor Representative for Continuous Supervision
January 17, 2025
Announcement on Resolution of the 2nd Meeting of the 2nd Board of Supervisors
January 3, 2025
Announcement on Abnormal Fluctuations in Stock Trading
December 24, 2024
Announcement on Completing Term Change of Board of Directors and Board of Supervisors, and Appointing Senior Management Members and Securities Affairs Representative
December 17, 2024
Announcement on Electing Employee Representative Supervisor of the 2nd Board of Supervisors
December 6, 2024
Announcement on Resolution of the 13th Meeting of the 1st Board of Supervisors
November 29, 2024